ABIONYX PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.024 EUR | +0.59% |
|
-4.66% | -20.50% |
| Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
| Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9.242 | 7.367 | 24.29 | 67.65 | 48.45 | 32.98 | 32.98 | - |
| Enterprise Value (EV) 1 | 3.288 | 0.1364 | 15.13 | 64.02 | 48.45 | 41.49 | 29.58 | 33.08 |
| P/E ratio | -1.44 x | 3.74 x | -12.4 x | -10.6 x | - | -7.31 x | -6.83 x | -5.69 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 46.2 x | - | - | 96.6 x | 9.14 x | 9.02 x | 7.17 x | 4.64 x |
| EV / Revenue | 16.4 x | - | - | 91.5 x | 9.14 x | 9.02 x | 6.43 x | 4.66 x |
| EV / EBITDA | -0.47 x | -0.05 x | -5.14 x | -11 x | - | -8.22 x | -5.19 x | -3.94 x |
| EV / FCF | -0.55 x | -0.03 x | - | -9.33 x | - | -7.83 x | -4.41 x | -3.48 x |
| FCF Yield | -183% | -2,895% | - | -10.7% | - | -12.8% | -22.7% | -28.7% |
| Price to Book | 2.37 x | 1.04 x | 3.36 x | 6.34 x | - | - | - | - |
| Nbr of stocks (in thousands) | 18,861 | 21,862 | 24,557 | 27,668 | 28,137 | 32,205 | 32,205 | - |
| Reference price 2 | 0.4900 | 0.3370 | 0.9890 | 2.445 | 1.722 | 1.024 | 1.024 | 1.024 |
| Announcement Date | 1/24/19 | 3/10/20 | 2/25/21 | 4/28/22 | 3/29/23 | 3/11/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.2 | - | - | 0.7 | 5.3 | 4.6 | 4.6 | 7.1 |
| EBITDA 1 | -7.013 | -2.512 | -2.946 | -5.833 | - | -4 | -5.7 | -8.4 |
| EBIT 1 | -7.1 | -2.5 | -3 | -5.952 | -4.109 | -3.4 | -6.3 | -9 |
| Operating Margin | -3,550% | - | - | -850.29% | -77.53% | -73.91% | -136.96% | -126.76% |
| Earnings before Tax (EBT) | -6.305 | 1.887 | -1.886 | -5.822 | - | - | - | - |
| Net income 1 | -6.3 | 1.8 | -1.9 | -5.822 | -4.206 | -3.5 | -6.5 | -9 |
| Net margin | -3,150% | - | - | -831.71% | -79.36% | -76.09% | -141.3% | -126.76% |
| EPS 2 | -0.3400 | 0.0900 | -0.0800 | -0.2300 | - | -0.1400 | -0.1500 | -0.1800 |
| Free Cash Flow 1 | -6.011 | -3.95 | - | -6.858 | - | -4.2 | -6.7 | -9.5 |
| FCF margin | -3,005.5% | - | - | -979.71% | - | -91.3% | -145.65% | -133.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 1/24/19 | 3/10/20 | 2/25/21 | 4/28/22 | 3/29/23 | 3/11/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2023 S1 |
|---|---|---|
| Net sales 1 | - | 2.13 |
| EBITDA | - | - |
| EBIT | -1.45 | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | - | -2.25 |
| Net margin | - | -105.63% |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 9/6/19 | 9/26/23 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 0.1 |
| Net Cash position 1 | 5.95 | 7.23 | 9.15 | 3.63 | - | 0.1 | 3.4 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -0.0119 x |
| Free Cash Flow 1 | -6.01 | -3.95 | - | -6.86 | - | -4.2 | -6.7 | -9.5 |
| ROE (net income / shareholders' equity) | -99.1% | 35.2% | - | -67.3% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 0.2100 | 0.3200 | 0.2900 | 0.3900 | - | - | - | - |
| Cash Flow per Share | -0.3200 | -0.1900 | -0.0300 | -0.2600 | - | - | - | - |
| Capex 1 | 0.01 | - | - | 0.17 | - | 0.1 | 0.1 | 0.1 |
| Capex / Sales | 5% | - | - | 23.71% | - | 2.17% | 2.17% | 1.41% |
| Announcement Date | 1/24/19 | 3/10/20 | 2/25/21 | 4/28/22 | 3/29/23 | 3/11/24 | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.024
EUR
Average target price
10.5
EUR
Spread / Average Target
+925.39%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.50% | 35.21M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ABNX Stock
- Financials ABIONYX Pharma
